23 October 2024
Health Care Law Today
GLP-1 Drugs: FDA Sued Over Removing Tirzepatide from the Drug Shortage List
Less than a week after the FDA determined that the shortage of the tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, has been “resolved” and removed from the FDA’s shortage list, the Outsourcing Facilities Association filed a lawsuit against the FDA relating to the agency’s removal of tirzepatide, from the FDA’s drug shortage list.